105 related articles for article (PubMed ID: 27628548)
1. [Safety Assessment of a Short Hydration Regimen for Outpatient Cisplatin-Based Chemotherapy].
Yoshida H; Kimata T; Suzuki M; Uchida T; Yamamuro O
Gan To Kagaku Ryoho; 2016 Sep; 43(9):1081-5. PubMed ID: 27628548
[TBL] [Abstract][Full Text] [Related]
2. [Cisplatin administration for outpatients with short hydration of less than four hours].
Hata A; Katakami N; Masuda Y; Kaji R; Fujita S; Iwamori S; Horai A; Takatori K; Ose T; Kitajima N; Mifune Y; Fukae M
Gan To Kagaku Ryoho; 2012 Sep; 39(9):1385-8. PubMed ID: 22996774
[TBL] [Abstract][Full Text] [Related]
3. [The feasibility of CDDP administration for gastric cancer outpatients undergoing S-1/cisplatin combination therapy].
Kishimoto T; Imamura H; Kawabata R; Kimura Y; Fujii C; Fukunaga M; Ohzato H
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2304-6. PubMed ID: 23268058
[TBL] [Abstract][Full Text] [Related]
4. [Nephrotoxicity of a Short Hydration Method for the Cisplatin Regimen in Patients with Gastric Cancer].
Kishi K; Saito T; Mikamori M; Ohtsuka M; Furukawa K; Suzuki Y; Tei M; Tanemura M; Akamatsu H
Gan To Kagaku Ryoho; 2018 Dec; 45(13):2069-2071. PubMed ID: 30692287
[TBL] [Abstract][Full Text] [Related]
5. [Feasibility of short volume hydration in patients with lung cancer treated with Cisplatin-containing chemotherapy].
Ohhara Y; Isobe H; Ito K; Fuke S; Kojima T; Saito H; Nishiura Y
Gan To Kagaku Ryoho; 2015 Jan; 42(1):57-61. PubMed ID: 25596680
[TBL] [Abstract][Full Text] [Related]
6. [Usefulness of oral rehydration solution for hydration in cancer chemotherapy: toward the application of outpatient chemotherapy with high-dose Cisplatin therapy-].
Sato J; Kudo K; Hino K; Takahashi K
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1471-6. PubMed ID: 21918344
[TBL] [Abstract][Full Text] [Related]
7. [Associations between Clinical Factors and Acute Renal Failure Due to Cisplatin Combination Chemotherapy for Lung Cancer].
Yamashita K; Yoshino M; Sasaki N; Tanaka Y; Tanaka K; Abe M; Tagawa C; Kawahara F; Kato K; Kaise M; Tanaka H; Chou T
Gan To Kagaku Ryoho; 2015 Nov; 42(11):1379-83. PubMed ID: 26602395
[TBL] [Abstract][Full Text] [Related]
8. A short outpatient hydration schedule for cisplatin administration.
Al Bahrani BJ; Moylan EJ; Forouzesh B; Della-Fiorentina SA; Goldrick AJ
Gulf J Oncolog; 2009 Jan; (5):30-6. PubMed ID: 20084783
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of Renal Toxicity of S-1 plus CDDP Regimen with Short Hydration for Outpatients with Gastric Cancer].
Hasegawa T; Teraoka H; Mori T; Kinoshita H; Nakamoto K; Noda E; Hirakawa K; Ohira M
Gan To Kagaku Ryoho; 2019 Dec; 46(13):2407-2409. PubMed ID: 32156947
[TBL] [Abstract][Full Text] [Related]
10. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis.
Numico G; Benasso M; Vannozzi MO; Merlano M; Rosso R; Viale M; Esposito M
Anticancer Res; 1998; 18(2B):1313-8. PubMed ID: 9615808
[TBL] [Abstract][Full Text] [Related]
11. Safety of a short hydration method for cisplatin administration in comparison with a conventional method-a retrospective study.
Sakaida E; Iwasawa S; Kurimoto R; Ebata T; Imai C; Oku T; Sekine I; Tada Y; Tatsumi K; Takiguchi Y
Jpn J Clin Oncol; 2016 Apr; 46(4):370-7. PubMed ID: 26755829
[TBL] [Abstract][Full Text] [Related]
12. [Feasibility of S-1/CDDP therapy for outpatients with advanced gastric cancer].
Rino Y; Murakami H; Yukawa N; Wada N; Oshima T; Matsuura H; Sugano N; Arai H; Masuda M; Imada T
Gan To Kagaku Ryoho; 2009 Nov; 36(11):1829-31. PubMed ID: 19920383
[TBL] [Abstract][Full Text] [Related]
13. Feasibility study of short hydration using oral rehydration solution in cisplatin including chemotherapy of lung cancer.
Sato J; Morikawa N; Nitanai H; Nagashima H; Nihei S; Yamauti K; Kudo K
J Pharm Health Care Sci; 2016; 2():6. PubMed ID: 26949541
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer.
Kobayashi K; Shinbara A; Kamimura M; Takeda Y; Kudo K; Kabe J; Hibino S; Hino M; Shibuya M; Kudoh S
Cancer Chemother Pharmacol; 1998; 42(1):53-8. PubMed ID: 9619758
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of weekly docetaxel-cisplatin as first-line treatment for advanced non-small cell lung cancer.
Binder D; Hackenthal M; Graseck L; Schweisfurth H; Schäper C; Krüll M; Temmesfeld-Wollbrück B; Suttorp N; Beinert T; Hellriegel KP
J Thorac Oncol; 2009 Sep; 4(9):1144-7. PubMed ID: 19609222
[TBL] [Abstract][Full Text] [Related]
16. [Combination therapy of a novel oral fluorouracil derivative TS-1 with low-dose cisplatin for recurrent and very advanced gastric cancer].
Nakata B; Hirakawa K
Gan To Kagaku Ryoho; 2004 Nov; 31(12):1962-8. PubMed ID: 15570921
[TBL] [Abstract][Full Text] [Related]
17. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
[TBL] [Abstract][Full Text] [Related]
18. [Retrospective analysis of pemetrexed plus cisplatin chemotherapy for elderly advanced non-small-cell lung cancer].
Ogasawara T; Kasamatsu N; Umezawa H; Takeuchi T; Naito Y; Hashizume I
Gan To Kagaku Ryoho; 2011 Nov; 38(11):1813-6. PubMed ID: 22083188
[TBL] [Abstract][Full Text] [Related]
19. Comparison of cisplatin-induced nephrotoxicity when using conventional versus short hydration in gastric cancer-a retrospective study.
Aoyama T; Tsunoda T; Kato H; Hagino A; Furutani R; Ito K; Yoshioka H; Nakamura M; Hiraide M; Kawakami K; Kobayashi K; Suzuki K; Ichimura T; Yamaguchi K; Hama T
J Chemother; 2020 May; 32(3):144-150. PubMed ID: 31960769
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
